Summary
At the eighth China International Import Expo (CIIE), New Zealand's a2 Milk Company launched three new infant formula products for the Chinese market. Two of these – a2 Zhi Chu Qi Run and a2 Zhi Chu Zhi Chun – are sourced and produced at a2's own factory, highlighting its supply chain autonomy. A regular CIIE exhibitor, a2 this year partnered with China State Farms Holdings Shanghai to release the two new products and an upgraded a2 Zi Bai Jin.
The upgraded Zi Bai Jin was launched simultaneously in Australia-New Zealand and China. David Bortolussi, Managing Director and CEO of a2 Milk Company, said China remains a key part of a2's global strategy. 'We are both participants in and beneficiaries of China's continued high-level opening-up,' he said.
The two new Zhi Chu family products are sourced and produced at a2's integrated nutrition manufacturing facility in Pokeno, North Island, New Zealand. The plant, New Zealand's newest world-class infant formula factory in nearly 20 years, has annual capacity of over 10 million cans and uses a wet process that turns fresh milk into powder in a single step. a2 has also pioneered an 'a2 batch-by-batch test report traceability system' that allows consumers to check test reports and traceability information for specific batches with one click.
The article notes that a2 leverages New Zealand milk sources and manufacturing capabilities to deepen product innovation around A2 protein research, and through its partnership with China State Farms Holdings Shanghai, brings global innovations to Chinese consumers.
Commentary
a2 Milk Company's launch of two new infant formula products made at its own Pokeno factory at CIIE underscores its supply chain autonomy strategy. The plant, with annual capacity of over 10 million cans and a single-step wet process, is New Zealand's newest infant formula factory in nearly 20 years. A regular CIIE exhibitor, a2 has partnered with China State Farms Holdings Shanghai and introduced a batch-by-batch traceability system to enhance quality transparency.
In the broader industry context, China's infant formula market is consolidating, with domestic brands such as Feihe and Yili dominating through channel penetration and formula registration advantages, putting pressure on foreign brands to localise. By controlling its supply chain through its own factory, a2 can reduce reliance on contract manufacturing, improve quality control and response times, and maintain a premium positioning backed by New Zealand milk sources. For NZ SMEs, a2's path shows that supply chain autonomy and local partnerships are key to breaking through in the Chinese market.
However, building factories requires huge investment; SMEs could consider deep ties with local contract manufacturers or joint research and development rather than blindly pursuing heavy assets. On the other hand, CIIE as a showcase platform offers NZ brands a window into Chinese consumer trends, but the infant formula market has entered stock competition, and new brands need to innovate in niche functions or channels. a2's batch-by-batch traceability system meets Chinese consumers' demand for transparency, and NZ SMEs can learn from this approach, using traceability as a differentiated selling point.
China continues to expand opening-up, but infant formula regulation is strict, and NZ companies need to pay attention to compliance requirements such as formula registration and labelling. a2's cooperation model with China State Farms offers a reference for NZ SMEs to enter the Chinese market with local partners, but partners should be chosen carefully to ensure brand control.
Keywords: a2 Milk Company, CIIE, new infant formula products, supply chain autonomy, Zhi Chu family, Pokeno factory, China State Farms Holdings Shanghai, A2 protein, traceability system, David Bortolussi
AI illustration on MiDeer Observer
Source: Eastmoney
Disclaimer: This article is compiled from publicly available sources for general information only. The analysis and commentary are editorial opinions. MiDeer Observer does not guarantee the accuracy or completeness of the information provided. Readers should seek independent professional advice before relying on this content, or contact us for more information.






